Fibromyalgia is a chronic pain disorder characterized by widespread musculoskeletal pain accompanied by symptoms such as fatigue, non-restorative sleep, cognitive difficulties, and psychological distress. It is increasingly understood as a nociplastic pain condition, in which abnormal processing and amplification of pain signals within the nervous system play an important role.
Fibromyalgia can substantially affect physical function, work, sleep, emotional well-being, and quality of life. However, it is important to recognize that fibromyalgia is a real and clinically recognizable disorder and should not be considered simply a diagnosis of exclusion.
The management of fibromyalgia has evolved considerably. Current recommendations emphasize patient education, individualized exercise, psychological interventions, treatment of sleep problems and comorbidities, and carefully selected medications rather than relying on medication alone.
The 2025 French Haute Autorité de Santé (HAS) guideline and the 2026 Brazilian Society of Rheumatology (SBR) guidelines provide important contemporary guidance for diagnosis, monitoring, and treatment.
What Is Fibromyalgia?
Fibromyalgia is a chronic pain syndrome characterized primarily by:
- Chronic widespread pain
- Increased pain sensitivity
- Fatigue
- Non-restorative or disturbed sleep
- Cognitive symptoms such as “brain fog”
- Headache
- Irritable bowel symptoms
- Mood symptoms, including anxiety or depression
- Reduced physical functioning
- Increased sensitivity to sensory stimuli in some patients
The underlying mechanisms are complex. Abnormal central pain processing, altered descending pain modulation, autonomic dysfunction, sleep disturbance, and interactions between biological and psychological factors may contribute.
Fibromyalgia is now generally considered within the spectrum of nociplastic pain, meaning that pain may arise from altered nociceptive processing without sufficient evidence of ongoing tissue damage or a lesion of the somatosensory system that fully explains the symptoms.
Importantly, fibromyalgia may coexist with other diseases, including rheumatoid arthritis, osteoarthritis, systemic lupus erythematosus, migraine, irritable bowel syndrome, chronic fatigue, and neuropathic disorders.
Who Develops Fibromyalgia?
Fibromyalgia can occur in both women and men and at different ages, although it is diagnosed more frequently in women.
Symptoms often develop gradually. Some patients report onset after:
- Physical trauma
- Surgery
- Infection
- Prolonged psychological stress
- Sleep disruption
- Another chronic pain condition
However, there is no single trigger in most patients.
Fibromyalgia may also coexist with other chronic medical conditions, which can make diagnosis and management more complicated.
Common Symptoms of Fibromyalgia
1. Widespread Pain
Pain is usually present in multiple regions of the body and may vary in location and intensity.
Patients may describe pain as:
- Aching
- Burning
- Deep muscular pain
- Stiffness
- Tenderness
- Sensitivity to touch
Pain severity can fluctuate considerably from day to day.
2. Fatigue
Fatigue is one of the most disabling symptoms. Patients may feel exhausted despite adequate time in bed and may experience reduced stamina during routine activities.
3. Sleep Disturbance
Common problems include:
- Difficulty falling asleep
- Frequent awakening
- Non-restorative sleep
- Early morning awakening
- Daytime sleepiness
Sleep disorders such as obstructive sleep apnea or restless legs syndrome should be considered when clinically appropriate.
4. Cognitive Symptoms
Patients frequently describe:
- Poor concentration
- Forgetfulness
- Difficulty finding words
- Reduced mental clarity
- Difficulty multitasking
These symptoms are commonly referred to by patients as “fibro fog.”
5. Headache and Other Symptoms
Some patients experience:
- Migraine or tension-type headache
- Irritable bowel symptoms
- Temporomandibular pain
- Pelvic pain
- Urinary symptoms
- Sensitivity to temperature, noise, light, or touch
The clinical presentation is heterogeneous, and not every patient has all of these symptoms.
How Is Fibromyalgia Diagnosed?
There is no single blood test, imaging study, or biomarker that confirms fibromyalgia.
Diagnosis is primarily clinical.
The 2016 revision of the American College of Rheumatology (ACR) criteria provides a useful framework for clinical diagnosis. The criteria incorporate:
- Widespread Pain Index (WPI)
- Symptom Severity Scale (SSS)
- Duration of symptoms
- Generalized distribution of pain
The 2016 criteria also allow fibromyalgia to be diagnosed when another medical condition is present; the presence of another disease does not automatically exclude fibromyalgia.
Practical diagnostic approach
Fibromyalgia should be considered when a patient has:
Chronic generalized pain + fatigue/sleep or cognitive symptoms + symptoms lasting ≥3 months.
The diagnosis should be made positively based on the clinical pattern rather than requiring an exhaustive search for every possible disease.
A detailed history and physical examination remain essential.
Should Laboratory Tests Be Ordered?
There is no laboratory test that establishes the diagnosis.
Testing should be guided by the clinical presentation rather than performed indiscriminately.
Depending on the history and examination, reasonable baseline investigations may include:
- Complete blood count
- ESR and/or CRP
- Thyroid-stimulating hormone
- Basic metabolic profile when appropriate
- Creatine kinase when muscle weakness suggests a myopathy
- Vitamin B12, vitamin D, iron studies, or other tests when clinically indicated
Additional investigations should be based on red flags or suspected alternative diagnoses.
A 2026 review emphasizes that fibromyalgia should be approached as a recognizable clinical syndrome rather than simply as a diagnosis made only after excluding every other disease.
Important Differential Diagnoses
Several conditions can produce widespread pain, fatigue, or sleep disturbance.
Consider:
- Rheumatoid arthritis
- Systemic lupus erythematosus
- Polymyalgia rheumatica
- Hypothyroidism
- Inflammatory myopathy
- Polymyositis/dermatomyositis
- Osteoarthritis
- Neuropathic pain
- Small-fiber neuropathy
- Vitamin B12 deficiency
- Iron deficiency
- Sleep apnea
- Chronic infection when clinically appropriate
- Medication-related myalgia
- Major depressive disorder
- Other chronic pain disorders
Red flags
Features that should prompt evaluation for another or additional diagnosis include:
- Objective joint swelling
- Persistent inflammatory arthritis
- Objective muscle weakness
- Fever
- Unexplained weight loss
- Significant abnormal inflammatory markers
- Neurological deficits
- Progressive focal symptoms
- Abnormal muscle enzymes
- Skin manifestations suggesting systemic disease
- Organ involvement
The presence of fibromyalgia does not protect a patient from developing another disease.
Fibromyalgia Is Not Simply “Inflammation”
Although some patients have inflammatory or immune abnormalities in research studies, fibromyalgia is not primarily considered an inflammatory rheumatic disease.
Routine treatment with corticosteroids or anti-inflammatory drugs is therefore not recommended simply because the patient has fibromyalgia.
The current approach focuses on abnormal pain processing, symptom amplification, physical deconditioning, sleep disturbance, and associated psychological and medical factors.
Treatment of Fibromyalgia: A Multidisciplinary Approach
The most important change in modern fibromyalgia management is the move away from a medication-centered approach.
Current guidelines emphasize:
- Patient education
- Exercise and physical activity
- Psychological interventions when appropriate
- Sleep management
- Treatment of comorbidities
- Individualized pharmacological treatment
- Regular monitoring of symptoms and function
The 2026 Brazilian Society of Rheumatology guideline specifically emphasizes interdisciplinary and patient-centered management.
1. Patient Education
Education is an essential component of treatment.
Patients should understand that:
- Fibromyalgia is a real medical condition.
- Pain does not necessarily indicate ongoing tissue damage.
- Symptoms may fluctuate.
- Complete elimination of pain is often unrealistic.
- Improving physical function, sleep, fatigue, and quality of life are important treatment goals.
- Treatment usually requires a combination of interventions.
- Improvement may take time.
Education can improve treatment adherence and help patients develop realistic expectations.
2. Exercise: One of the Most Important Treatments
Exercise remains a central component of fibromyalgia management.
The evidence supports individualized physical activity, particularly:
Aerobic exercise
Examples include:
- Walking
- Cycling
- Swimming
- Water-based exercise
Resistance training
Strength training can improve:
- Muscle strength
- Physical function
- Exercise tolerance
- Quality of life
Flexibility and mobility exercises
Stretching and mobility exercises may be useful as part of a broader program.
The 2026 Brazilian guideline recommends physical activity, particularly programs incorporating aerobic and resistance exercise, as an important component of management.
The key principle is start low and progress gradually.
Patients who are severely deconditioned should not be expected to immediately perform high-intensity exercise.
A practical approach is:
Start → tolerate → repeat → gradually increase.
Temporary mild increases in symptoms can occur when starting exercise and do not necessarily indicate injury.
3. Psychological Therapies
Psychological interventions do not mean that fibromyalgia is “all in the patient’s head.”
Psychological therapies can modify pain perception, coping strategies, sleep, stress responses, and functional disability.
Cognitive Behavioral Therapy (CBT)
CBT may help patients:
- Manage chronic pain
- Reduce catastrophizing
- Improve coping
- Improve sleep
- Reduce psychological distress
Acceptance and Commitment Therapy (ACT)
ACT may help patients develop strategies for living with chronic symptoms while maintaining meaningful activities.
The 2026 Brazilian guideline identifies psychological interventions, including CBT and ACT, as useful components of multidisciplinary care.
4. Sleep Management
Sleep should be assessed systematically because poor sleep can amplify pain and fatigue.
Look for:
- Insomnia
- Obstructive sleep apnea
- Restless legs syndrome
- Circadian rhythm problems
- Medication-related sleep disturbance
Sleep hygiene should be addressed.
Treatment should target the specific sleep disorder when one is identified.
A 2025 systematic review and network meta-analysis evaluated pharmacological and non-pharmacological interventions for sleep problems in fibromyalgia, highlighting the importance of sleep as a specific therapeutic target.
5. Pharmacological Treatment
Medications should be considered when symptoms remain clinically significant despite non-pharmacological interventions or when specific symptoms/comorbidities justify pharmacotherapy.
The goal is usually to:
- Reduce pain
- Improve sleep
- Reduce fatigue when possible
- Improve function
- Improve quality of life
No medication reliably controls every symptom of fibromyalgia.
Amitriptyline
Low-dose amitriptyline may be useful particularly when patients have:
- Sleep disturbance
- Chronic pain
- Headache
It is generally started at a low dose and adjusted according to response and adverse effects.
Potential adverse effects include:
- Dry mouth
- Constipation
- Orthostatic hypotension
- Sedation
- Weight gain
- Anticholinergic effects
Caution is needed in older adults and patients with cardiac conduction abnormalities, glaucoma, urinary retention, or significant anticholinergic burden.
6. Duloxetine
Duloxetine is a serotonin-norepinephrine reuptake inhibitor (SNRI) with evidence for reducing fibromyalgia pain in some patients.
It may be particularly useful when fibromyalgia coexists with:
- Depression
- Anxiety
- Neuropathic-type pain
Common adverse effects include:
- Nausea
- Dry mouth
- Sweating
- Insomnia or somnolence
- Sexual dysfunction
The 2026 Brazilian guideline identifies duloxetine among medications with evidence supporting its use in appropriate patients.
7. Pregabalin
Pregabalin may improve:
- Pain
- Sleep
- Quality of life
Adverse effects include:
- Dizziness
- Somnolence
- Peripheral edema
- Weight gain
- Cognitive effects
Dose adjustment is required in patients with reduced renal function.
Pregabalin should be prescribed selectively based on the patient’s symptom pattern, comorbidities, renal function, and risk of adverse effects.
8. Gabapentin
Although gabapentin is sometimes used in clinical practice, evidence is less robust than for pregabalin.
The 2026 Brazilian guideline does not identify sufficient evidence to formally recommend gabapentin for fibromyalgia.
9. SSRIs
Selective serotonin reuptake inhibitors (SSRIs) may be appropriate for an independent diagnosis of depression or anxiety.
However, they should not automatically be considered primary analgesic treatment for fibromyalgia.
Their role should therefore be determined by the patient’s comorbid psychiatric symptoms and overall treatment plan.
10. Opioids
Routine opioid treatment is not recommended for fibromyalgia.
Reasons include:
- Limited evidence of long-term benefit
- Risk of dependence
- Tolerance
- Sedation
- Constipation
- Potential opioid-related adverse effects
- Risk of opioid-induced hyperalgesia
The 2026 Brazilian guideline specifically advises against routine opioid use for fibromyalgia.
11. NSAIDs and Corticosteroids
NSAIDs generally have limited usefulness for the core symptoms of fibromyalgia because the condition is not primarily driven by peripheral inflammation.
They may be used when there is a separate indication, such as osteoarthritis or another painful musculoskeletal condition.
Similarly, corticosteroids should not be used as routine treatment for fibromyalgia.
12. Benzodiazepines
Benzodiazepines are not recommended as routine treatment for fibromyalgia.
Long-term use can cause:
- Dependence
- Tolerance
- Sedation
- Cognitive impairment
- Falls
- Withdrawal symptoms
Sleep problems should preferably be managed with appropriate behavioral and sleep-focused interventions and, when indicated, targeted pharmacological treatment.
The 2026 Brazilian guideline does not recommend routine benzodiazepine therapy for fibromyalgia.
13. Complementary and Other Therapies
Some patients may benefit from selected complementary approaches.
Depending on availability, preferences, and clinical circumstances, these may include:
- Acupuncture
- Tai Chi
- Mindfulness-based approaches
- Yoga
- Relaxation techniques
- Hydrotherapy
- Selected neuromodulation approaches
However, these should generally complement rather than replace evidence-based exercise, education, and appropriate medical management.
The 2026 Brazilian guideline discusses acupuncture and neuromodulation among approaches that may provide symptom relief, particularly for pain.
14. Diet and Nutritional Supplements
A balanced diet should be encouraged, but there is currently no universally recommended specific fibromyalgia diet.
Patients should be encouraged to:
- Eat a balanced diet
- Maintain a healthy body weight
- Avoid excessive ultra-processed foods
- Correct documented nutritional deficiencies
- Maintain adequate protein and micronutrient intake
The 2026 Brazilian guideline concludes that there is insufficient evidence to support one specific dietary strategy or nutritional supplement as a standard treatment for fibromyalgia.
Weight reduction may be appropriate for patients with obesity because improving overall metabolic health and physical function can contribute to better outcomes.
How Should Treatment Response Be Monitored?
Treatment should not be assessed only by asking:
“Is your pain better?”
A broader assessment should include:
- Pain intensity
- Fatigue
- Sleep quality
- Cognitive symptoms
- Physical function
- Mood
- Work/activity participation
- Quality of life
Validated instruments can be useful.
The Revised Fibromyalgia Impact Questionnaire (FIQR) is one commonly used tool for assessing overall disease impact.
The Fibromyalgia Survey Questionnaire (FSQ) can also help quantify symptom burden.
The 2026 Brazilian guideline emphasizes structured monitoring using validated instruments such as FIQR and FSQ.
Setting Realistic Treatment Goals
A successful treatment program does not necessarily mean complete elimination of pain.
Meaningful goals may include:
- Walking farther
- Returning to work
- Sleeping better
- Reducing fatigue
- Improving concentration
- Increasing physical activity
- Reducing dependence on medications
- Improving quality of life
A useful clinical question is:
“What activity would you most like to be able to do again?”
Treatment can then be structured around that functional goal.
A Practical 2026 Treatment Algorithm
Step 1 — Confirm the clinical diagnosis
Assess:
- Generalized pain
- Symptom duration ≥3 months
- Fatigue
- Sleep disturbance
- Cognitive symptoms
- Physical examination
- ACR 2016 criteria when useful
Step 2 — Look for red flags
Investigate alternative or additional diagnoses when there is:
- Objective weakness
- Joint swelling
- Fever
- Weight loss
- Neurological deficit
- Significant inflammatory abnormalities
- Other organ-specific findings
Step 3 — Identify comorbidities
Assess for:
- Depression
- Anxiety
- Insomnia
- Sleep apnea
- Migraine
- IBS
- Osteoarthritis
- Neuropathic pain
- Obesity
Step 4 — Educate the patient
Explain the nature of fibromyalgia and establish realistic expectations.
Step 5 — Start individualized exercise
Begin with tolerable activity and gradually increase duration and intensity.
Step 6 — Address sleep and psychological factors
Use sleep interventions and consider CBT/ACT when appropriate.
Step 7 — Consider medication when indicated
Select medication according to the dominant symptom pattern and comorbidities.
Examples include:
- Amitriptyline
- Duloxetine
- Pregabalin
Step 8 — Monitor response
Assess:
- Pain
- Sleep
- Fatigue
- Function
- Mood
- Quality of life
- Medication adverse effects
Step 9 — Adjust treatment
Continue effective interventions, discontinue ineffective or poorly tolerated medications, and reconsider the diagnosis if the clinical picture changes.
Key Messages for Patients
Fibromyalgia is a real and treatable chronic pain condition.
The most important principles are:
- There is no single test that confirms fibromyalgia.
- The diagnosis is primarily clinical.
- Fibromyalgia can coexist with other diseases.
- Exercise is a cornerstone of treatment.
- Education and self-management are essential.
- Sleep problems should be actively addressed.
- Psychological therapies can improve coping, function, and symptoms.
- Medications should be individualized.
- Opioids, benzodiazepines, routine NSAIDs, and corticosteroids are not appropriate routine treatments for fibromyalgia.
- Treatment should focus not only on pain but also on function and quality of life.
- Improvement is often gradual and requires long-term follow-up.
When Should a Patient See a Doctor?
Medical evaluation is particularly important when widespread pain is accompanied by:
- Unexplained fever
- Unintentional weight loss
- Persistent joint swelling
- Significant muscle weakness
- Progressive neurological symptoms
- Severe fatigue with other systemic symptoms
- Abnormal laboratory findings
- New symptoms that are substantially different from the patient’s usual pattern
These findings may indicate another condition in addition to, or instead of, fibromyalgia.
Conclusion
Fibromyalgia is a complex chronic pain condition characterized by widespread pain and a broad range of associated symptoms, including fatigue, sleep disturbance and cognitive difficulties.
Modern management has shifted from simply prescribing analgesic medication toward a multidisciplinary, patient-centered strategy.
The strongest and most consistent components of care include patient education, individualized physical activity/exercise, appropriate psychological interventions, sleep management, treatment of comorbidities, and selective use of pharmacological therapy.
The 2025 French HAS guideline and the 2026 Brazilian Society of Rheumatology guidelines reinforce this approach. Although pharmacological treatments such as amitriptyline, duloxetine and pregabalin may benefit selected patients, no single medication is sufficient for all patients, and routine use of opioids and several other medications is discouraged.
Fibromyalgia treatment should therefore be individualized, monitored over time, and directed toward better function, improved sleep, reduced symptom burden and a better quality of life, rather than focusing exclusively on eliminating pain.
References
- Heymann RE, Rezende MC, Braz AS, et al. Brazilian Society of Rheumatology’s fibromyalgia treatment guidelines – part I: monitoring and non-pharmacological management. Advances in Rheumatology. 2026;66:10. doi:10.1186/s42358-025-00507-x.
- Heymann RE, Rezende MC, Paiva ES, et al. Review of fibromyalgia treatment guidelines: part 2 – pharmacological treatment. Advances in Rheumatology. 2026;66:9. doi:10.1186/s42358-025-00483-2.
- Haute Autorité de Santé (HAS). Fibromyalgia in adults: Diagnostic process and treatment strategy. Clinical Practice Guideline. July 2025.
- Wolfe F, Clauw DJ, Fitzcharles MA, et al. 2016 Revisions to the 2010/2011 fibromyalgia diagnostic criteria. Seminars in Arthritis and Rheumatism. 2016;46(3):319-329. doi:10.1016/j.semarthrit.2016.08.012.
- Macfarlane GJ, Kronisch C, Dean LE, et al. EULAR revised recommendations for the management of fibromyalgia. Annals of the Rheumatic Diseases. 2017;76:318-328.
- Devigili G, Di Stefano G, Donadio V, et al. Therapeutic approach to fibromyalgia: a consensus statement on pharmacological and non-pharmacological treatment from the neuropathic pain special interest group of the Italian Neurological Society. Neurological Sciences. 2025. doi:10.1007/s10072-025-08048-3.
- Hudson M, et al. Effects of Pharmacologic and Nonpharmacologic Interventions for the Management of Sleep Problems in People With Fibromyalgia: Systematic Review and Network Meta-Analysis of Randomized Controlled Trials. Arthritis Care & Research. 2025;77(9):1095-1105. doi:10.1002/acr.25505.
- Segura-Jiménez V. Advancing insights into fibromyalgia: an updated review of diagnosis and differential diagnosis. Expert Review of Neurotherapeutics. 2026. doi:10.1080/14737175.2026.2733188.
- Bazzichi L, Di Carlo M, Salaffi F, et al. Therapeutic advances in fibromyalgia: one year in review 2026. Clinical and Experimental Rheumatology. 2026;44(6):1069-1081.
Medical disclaimer: This article is intended for general educational purposes and does not replace an individualized medical assessment. Diagnosis and treatment should be determined by a qualified healthcare professional based on the patient’s clinical presentation, comorbidities, medications, and risk factors.